Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

BEAM-MM - β-Hydroxybutyrate-Enhanced Adaptive Immunity in Multiple Myeloma

NCT07564219 is registered in ClinicalTrials.gov with Universitätsklinikum Hamburg-Eppendorf as lead sponsor.

NCT NCT07564219
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07564219 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
BEAM-MM - β-Hydroxybutyrate-Enhanced Adaptive Immunity in Multiple Myeloma
Lead sponsor
Universitätsklinikum Hamburg-Eppendorf
Phase
Not applicable
Overall status
Recruiting
Start date
January 30, 2026
Completion date
December 31, 2028
Enrollment
45 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bispecific antibodies, car t cells, multiple myeloma (mm)